Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Volkmar Henschel

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology

English

Related publications

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology

Respiratory Medicine

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

Cancer Research

Respiratory Medicine

English

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research

Cancer Research

English

Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial

Clinical Cancer Research

Cancer Research

English

Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Annals of Translational Medicine

English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK

Journal of Thoracic Oncology

Respiratory Medicine

English